BioCardia to Present at the 9th Annual Biotech Showcase in San Francisco

January 09, 2017

SAN CARLOS, CABioCardia®, Inc.[OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that it is scheduled to present at the 9th Annual Biotech Showcase, being held on January 9-11, 2017 at the Hilton San Francisco Union Square in San Francisco, CA.

Dr. Peter Altman, Chief Executive Officer, will provide an update of the Company’s business during the live presentation and will be available for face-to-face conversations with conference attendees. Details for the presentation are as follows: Date: Monday, January 9, 2017 Time: 11:00AM PST.


About BioCardia®:
BioCardia, Inc., headquartered in San Carlos, CA, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP® and CardiALLO® cell therapies are the company’s biotherapeutic product candidates in clinical development. The Company's current products include the Helix™ transendocardial delivery system and the Morph® steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.

MEDIA CONTACTS
For BioCardia
Investors and Media:
David McClung, Vice President Finance & CFO
Email: investors@BioCardia.com 
Phone: 650-226-0120

News


Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.